156 related articles for article (PubMed ID: 26623043)
1. Characteristics of colorectal tumours in asymptomatic patients with negative immunochemical faecal occult blood test results.
Wakamura K; Kudo SE; Miyachi H; Kodama K; Hayashi S; Maeda Y; Ogawa Y; Kouyama Y; Kataoka SI; Kato K; Ichimasa K; Misawa M; Mori Y; Kudo T; Hayashi T; Ishida F; Ohkoshi S
Mol Clin Oncol; 2015 Sep; 3(5):1019-1024. PubMed ID: 26623043
[TBL] [Abstract][Full Text] [Related]
2. The factors associated with negative colonoscopy in screening subjects with positive immunochemical stool occult blood test outcomes.
Ting PH; Lin XH; Jiang JK; Luo JC; Chen PH; Wang YP; Hsin IF; Perng CL; Hou MC; Lee FY
J Chin Med Assoc; 2018 Sep; 81(9):759-765. PubMed ID: 29778550
[TBL] [Abstract][Full Text] [Related]
3. Colorectal screening using the immunochemical faecal occult blood test kit among the Malaysian cohort participants.
Abdullah N; Abd Jalal N; Ismail N; Kamaruddin MA; Abd Mutalib NS; Alias MR; Mazlan L; Sagap I; Jamal R
Cancer Epidemiol; 2020 Apr; 65():101656. PubMed ID: 31923638
[TBL] [Abstract][Full Text] [Related]
4. Determinants of colorectal carcinoma screening amongst patients attending a public primary care health centre in Johor Bahru.
Rizky NPH; Aznida FAA; Wan Fadhilah WI
Med J Malaysia; 2021 May; 76(3):346-352. PubMed ID: 34031333
[TBL] [Abstract][Full Text] [Related]
5. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.
Duffy MJ; van Rossum LG; van Turenhout ST; Malminiemi O; Sturgeon C; Lamerz R; Nicolini A; Haglund C; Holubec L; Fraser CG; Halloran SP
Int J Cancer; 2011 Jan; 128(1):3-11. PubMed ID: 20824704
[TBL] [Abstract][Full Text] [Related]
6. To scope or not - the challenges of managing patients with positive fecal occult blood test after recent colonoscopy.
Rattan N; Willmann L; Aston D; George S; Bassan M; Abi-Hanna D; Anandabaskaran S; Ermerak G; Ng W; Koo JH
World J Gastrointest Oncol; 2022 Sep; 14(9):1798-1807. PubMed ID: 36187395
[TBL] [Abstract][Full Text] [Related]
7. Immunochemical faecal occult blood test for colorectal cancer screening: a systematic review.
Syful Azlie MF; Hassan MR; Junainah S; Rugayah B
Med J Malaysia; 2015 Feb; 70(1):24-30. PubMed ID: 26032525
[TBL] [Abstract][Full Text] [Related]
8. Performance value of high risk factors in colorectal cancer screening in China.
Meng W; Cai SR; Zhou L; Dong Q; Zheng S; Zhang SZ
World J Gastroenterol; 2009 Dec; 15(48):6111-6. PubMed ID: 20027686
[TBL] [Abstract][Full Text] [Related]
9. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
Van Roosbroeck S; Hoeck S; Van Hal G
Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
[TBL] [Abstract][Full Text] [Related]
10. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort.
Chen LS; Yen AM; Chiu SY; Liao CS; Chen HH
Lancet Oncol; 2011 Jun; 12(6):551-8. PubMed ID: 21592859
[TBL] [Abstract][Full Text] [Related]
11. Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies.
Hirai HW; Tsoi KK; Chan JY; Wong SH; Ching JY; Wong MC; Wu JC; Chan FK; Sung JJ; Ng SC
Aliment Pharmacol Ther; 2016 Apr; 43(7):755-64. PubMed ID: 26858128
[TBL] [Abstract][Full Text] [Related]
12. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; Jansen JB; Verbeek AL; Dekker E
Br J Cancer; 2009 Oct; 101(8):1274-81. PubMed ID: 19755997
[TBL] [Abstract][Full Text] [Related]
13. [Sensitivity of immunochemical occult blood testing in detecting early colorectal cancer].
Saito H
Nihon Rinsho; 1996 May; 54(5):1421-4. PubMed ID: 8965378
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
[TBL] [Abstract][Full Text] [Related]
15. Implementation of immunochemical faecal occult blood test in general practice: a study protocol using a cluster-randomised stepped-wedge design.
Juul JS; Bro F; Hornung N; Andersen BS; Laurberg S; Olesen F; Vedsted P
BMC Cancer; 2016 Jul; 16():445. PubMed ID: 27400657
[TBL] [Abstract][Full Text] [Related]
16. The Effects of Direct Oral Anticoagulants, Warfarin, Aspirin and Thienopyridine on the Performance of Immunochemical, Faecal, Occult Blood Tests.
Niikura R; Yamada A; Fujishiro M; Tanaka K; Matsuda K; Saito Y; Ohtsuka K; Oda I; Katada C; Kato M; Kida M; Kobayashi K; Hoteya S; Horimatsu T; Kodashima S; Matsuda T; Muto M; Yamamoto H; Ryozawa S; Iwakiri R; Kutsumi H; Miyata H; Kato M; Haruma K; Fujimoto K; Uemura N; Kaminishi M; Shinozaki T; Tajiri H; Koike K
Digestion; 2019; 100(2):117-126. PubMed ID: 30408803
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of different screening strategies for colorectal cancer in Guangzhou, southern China: a Markov simulation analysis based on natural community screening results.
Zhou Q; Li HL; Li Y; Gu YT; Liang YR; Liu HZ; Li K; Dong H; Chen YY; Lin GZ
BMJ Open; 2021 Sep; 11(9):e049581. PubMed ID: 34489283
[TBL] [Abstract][Full Text] [Related]
18. Combined Plasma MicroRNA and Fecal Occult Blood Tests in Early Detection of Colorectal Cancer.
Luo X; Wu Y; Ji M; Zhang S
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115212
[TBL] [Abstract][Full Text] [Related]
19. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients.
Li S; Wang H; Hu J; Li N; Liu Y; Wu Z; Zheng Y; Wang H; Wu K; Ye H; Rao J
Int J Cancer; 2006 Jun; 118(12):3078-83. PubMed ID: 16425283
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
